Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) fell 7.1% during mid-day trading on Tuesday . The company traded as low as $7.08 and last traded at $7.08, with a volume of 98,527 shares traded. The stock had previously closed at $7.62.

A number of brokerages have issued reports on KPTI. Leerink Swann reiterated a “buy” rating on shares of Karyopharm Therapeutics in a research note on Sunday, June 12th. Canaccord Genuity reiterated a “buy” rating and set a $20.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, April 6th. Zacks Investment Research lowered shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 12th. Robert W. Baird began coverage on shares of Karyopharm Therapeutics in a research note on Monday, June 27th. They set an “outperform” rating and a $16.00 price target on the stock. Finally, Raymond James Financial Inc. began coverage on shares of Karyopharm Therapeutics in a research note on Friday, May 27th. They set an “outperform” rating and a $13.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $19.50.

The stock’s 50-day moving average price is $7.92 and its 200 day moving average price is $7.96. The firm’s market capitalization is $255.32 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Monday, May 9th. The company reported ($0.75) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.74) by $0.01. On average, analysts anticipate that Karyopharm Therapeutics Inc. will post ($3.09) EPS for the current fiscal year.

In other news, major shareholder Ltd Chione sold 10,400 shares of Karyopharm Therapeutics stock in a transaction dated Monday, May 16th. The stock was sold at an average price of $8.01, for a total value of $83,304.00. Following the transaction, the insider now directly owns 8,967,732 shares of the company’s stock, valued at approximately $71,831,533.32. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

An institutional investor recently raised its position in Karyopharm Therapeutics stock. Mutual of America Capital Management LLC boosted its stake in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) by 60.3% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 88,066 shares of the company’s stock after buying an additional 33,129 shares during the period. Mutual of America Capital Management LLC owned about 0.25% of Karyopharm Therapeutics worth $1,167,000 at the end of the most recent quarter.

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company focused on the discovery and development of drugs directed against nuclear transport targets for the treatment of cancer and other diseases. The Company is developing small molecule Selective Inhibitor of Nuclear Export (SINE), compounds that inhibits the nuclear export protein XPO1.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.